Patients #3 and #9 had both been on Luspatercept.
Posted: Thu Mar 21, 2024 8:59 pm
Both of our ODAC patient success stories (#3 and #9) involved each patient being on Luspatercept prior to Imetelstat.
Patient #3 was on Luspatercept from Aug'22 to Feb'23 (~6 months). You can hear her comments at the 4:34:40 mark. Basically, she states that Luspatercept "helped some (she thinks) but it returned less than acceptable results". She noticed a significant improvement ~6 weeks after starting on Imetelstat, and she's been transfusion free for 8+ months. She was taking blood transfusions on a ~biweekly basis prior to Imetelstat treatment.
Patient #9 was put on Luspatercept in Jun'22. He doesn't comment specifically on his experience with Luspatercept, but he was enrolling in the Imetelstat trial in May'23 (~11 months later). Like Patient #3, he was initially treated with Placebo (2 rounds) before being switched over to Imetelstat in Aug'23. He had a total of thirteen (13) transfusions between 4/20/23 to 9/7/23. He began his Imetelstat treatment on 8/7/23 with his hemoglobin increasing from a low of 6.6 (Sep'23) to 13.1 (Dec'23) as a result of his Imetelstat treatment. His comments can be heard at the 5:07:50 mark of the video.
https://www.youtube.com/watch?v=Om-cKKBsMS4
Let's hope the FDA is aware & considerate of these two stories when considering the use of Imetelstat following Luspatercept treatment. Further, both of these stories involve US-based patients.
Patient #3 was on Luspatercept from Aug'22 to Feb'23 (~6 months). You can hear her comments at the 4:34:40 mark. Basically, she states that Luspatercept "helped some (she thinks) but it returned less than acceptable results". She noticed a significant improvement ~6 weeks after starting on Imetelstat, and she's been transfusion free for 8+ months. She was taking blood transfusions on a ~biweekly basis prior to Imetelstat treatment.
Patient #9 was put on Luspatercept in Jun'22. He doesn't comment specifically on his experience with Luspatercept, but he was enrolling in the Imetelstat trial in May'23 (~11 months later). Like Patient #3, he was initially treated with Placebo (2 rounds) before being switched over to Imetelstat in Aug'23. He had a total of thirteen (13) transfusions between 4/20/23 to 9/7/23. He began his Imetelstat treatment on 8/7/23 with his hemoglobin increasing from a low of 6.6 (Sep'23) to 13.1 (Dec'23) as a result of his Imetelstat treatment. His comments can be heard at the 5:07:50 mark of the video.
https://www.youtube.com/watch?v=Om-cKKBsMS4
Let's hope the FDA is aware & considerate of these two stories when considering the use of Imetelstat following Luspatercept treatment. Further, both of these stories involve US-based patients.